Teva Pharmaceutical Industries Limited Q2 2025 Earnings Recap

TEVA Q2 2025 July 30, 2025

Get alerts when TEVA reports next quarter

Teva Pharmaceutical Industries reported solid Q2 2025 results, marking its 10th consecutive quarter of growth driven by strong performance in its innovative product portfolio, while overall revenues reached $4.2 billion, up 1%.

Earnings Per Share Beat

$0.66 vs $0.63 est.

+4.8% surprise

Revenue Miss

4176000000 vs 4361502790 est.

-4.3% surprise

Market Reaction

1-Day -8.2%

5-Day -4.87%

30-Day +9.21%

See TEVA alongside your other holdings

Add to your portfolio — free

Key Takeaways

Adjusted EBITDA increased by 7%, and non-GAAP EPS rose 10%.
Significant growth in innovative drugs: AUSTEDO up 19% to nearly $500 million, UZEDY up 120% to $54 million, and AJOVY up 31% to $155 million.
The global generics business saw a decline of 2% amid strong prior year comparisons.
Teva remains on track with its cost transformation programs, expecting to achieve mid-single-digit growth targets for 2027.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit TEVA on AllInvestView.

Next Q3 2025